Introduction
Trefoil factors TFF1 (formerly designated pS2), TFF2 (Spasmolytic Polypeptide), and TFF3 (intestinal trefoil factor) are 7-12 kDa protease-resistant proteins mainly secreted by mucus-secreting cells in the gastrointestinal tract (reviewed in Emami et al., 2004) . TFFs are efficient motogenic agents with beneficial effects on the gastrointestinal epithelia, promoting wound healing and mucosal restitution after local injury. Although some studies argue for a therapeutic potential of TFFs in mucosal injury and wound healing (Babyatsky et al., 1996; Taupin and Podolsky, 2003) , recent advances in the field support their adverse effects during chronic inflammation and cancer progression. We have recently proposed that TFF1 exerts dual roles in the digestive mucosa. TFF1 protects injured gastric mucosal epithelial cells (Kindon et al., 1995; Tomasetto et al., 2000) and accordingly gastric TFF1-deficient mice develop antro-pyloric adenomas and carcinomas. Thus, TFF1 is a candidate gastric-specific tumor suppressor to protect the mucosa against acid, digestive enzymes and pathogens, such as Helicobacter pylori (Rio et al., 1988; Lefebvre et al., 1996; Van De Bovenkamp et al., 2005) . In contrast, TFF1 is absent in normal colon but is induced at high levels in Crohn disease and colorectal cancers (Emami et al., 2004) . Recent studies incriminate TFF1 and other TFFs in the neoplastic progression of the digestive system, according to their scattering, proinvasive and proangiogenic activities in vitro and in vivo (Emami et al., 2001; Rodrigues et al., 2001 Rodrigues et al., , 2003b Rivat et al., 2005) . All TFF members are implicated in cancer cell survival, suggesting that they participate to the aggressive behavior and metastatic potential of colon cancer cells (Taupin et al., 2000; BossenmeyerPourie et al., 2002; Yio et al., 2005) . These studies suggest that divergent effects are associated with the status of TFF1 in the gastrointestinal mucosa during normal development, chronic inflammation, and neoplastic progression.
In order to further investigate on this concept, we examined the status and functional role of TFF1 at the adenoma and adenocarcinoma transitions in human colorectal tumors and in vitro, using as model the premalignant adenomatous PC/AA/C1 cell line (designated PC) isolated from a patient with familial adenomatous polyposis FAP (Williams et al., 1994) . Several biological and molecular parameters were also investigated in premalignant and tumorigenic colorectal and kidney cancer cells, including anchorage-independent growth, cell survival and invasion, growth of tumor xenografts, and identification of TFF1 target genes.
Results

Induction of TFF1 at the adenoma and carcinoma transitions
The transforming functions of TFFs in the digestive tract and other solid tumors are supported by their positive actions on tumor cell invasion, angiogenesis and survival (Emami et al., 2001; Bossenmeyer-Pourie et al., 2002; Rodrigues et al., 2003a, b) . To our knowledge, the status and biological significance of TFF1 at the adenoma and carcinoma transitions in the intestine has not been elucidated.
As shown in Figure 1a , TFF1 was undetectable by immunochemistry in normal human colon epithelial crypts and their surrounding connective tissue. In contrast, TFF1 is highly expressed in colon epithelial cells from hyperplastic polyps, and expressed with various intensity in all cases of adenomas and adenocarcinomas of the four groups of genetic background FAP, HNPCC and sporadic MSI þ and MSIÀ colon cancers (Figure 1b-f ). This immunohistochemical analysis clearly illustrates that TFF1 is progressively induced at the transitions between normal mucosa and adenomas. In agreement with previous studies on sporadic colon cancers (Shousha et al., 1993; Emami et al., 2001) , TFF1 staining remains persistent during further progression to aggressive carcinomas (Figure 1d and f). Thus, our data support the idea that TFF1 protein induction and persistence in transformed colon epithelial cells may contribute to the early and late stages of the neoplastic progression. In order to validate this hypothesis, we further explored the transforming potential of TFF1 in premalignant PC adenoma cells.
Ectopic expression of TFF1 confers anchorageindependent growth and constitutive invasive phenotypes Consistent with their origin, we have previously shown that the premalignant adenomatous colon epithelial cells PC are not tumorigenic in the nude mice and are not spontaneously invasive in collagen type I gels (Empereur et al., 1997) . Interestingly, forced expression of TFF1 in PC cells is associated with the induction of the invasive phenotype ( Figure 2a , left panel). Similar response was observed after transfer of the TFF1 expression vector in parental MDCK epithelial cells (not shown), srctransformed MDCKts.src kidney cancer cells (Figure 2a, right panel) , and HCT8/S11 colon cancer cells (Emami et al., 2001) . These invasive responses observed in PC-TFF1 and MDCKts.src-TFF1 cells are blocked by pharmacological inhibitors targeting several oncogenic pathways implicated in cell motility, invasion and survival, including Rho GTPases (C3T, 3 mg/ml), Rho-kinase (Y27632, 10 mM), PI3 0 -kinase (WORT, 10 nM), PLCb (U73122, 1 mM), and COX-2 (NS398, 25 mM). According to our previous report (Rodrigues et al., 2001) , TFF1 overexpression was associated with increased levels of the COX-2 protein.
To further assess the transforming potential of TFF1, we compared the ability of adenomatous PC cells and TFF1-transformed PC-TFF1 cells to grow in soft agar. As shown in Figure 2b (left panels), TFF1 remarkably Figure 1 Detection of TFF1 by immunohistochemistry in human colon hyperplastic polyps, adenomas, carcinomas, and normal colon mucosa. Representative sections of normal human colon mucosa (a), hyperplasic polyps (b), FAP and HNPCC adenomas (c and e) and carcinomas (d and f) were analyzed for TFF1 immunoreactivity, using the p2802 mAb antibody directed against human TFF1. Magnifications: Â 100 (b), Â 250 (a and f), and Â 400 (c-e).
TFF1 transforming functions and Cdc25 phosphatases S Rodrigues et al increased 4.6-fold the growth of PC-TFF1 cells in soft agar, as judged by the number and size of the colonies growing inside the gels, in comparison with their control PC-pcDNA3 counterparts. Our data illustrate for the first time the transforming property of TFF1 on anchorage-independent growth linked to cell adhesion and survival mechanisms. Interestingly, a weaker but significant transforming effect of TFF1 is observed in MDCKts.src-TFF1 cells, as compared to mock-transfected cells (Po0.05, Figure 2b , right panels). Similar data was observed in HCT8/S11 human colon cells established from a sporadic colon cancer. Ectopic expression of TFF1 in this cancer cell line gave no additional colony number formation but had a strong impact on colony size (not shown). Altogether, these results indicate that TFF1 exerts transforming functions in a series of colon and kidney epithelial cells at different stages of the neoplastic progression.
Promotion and accentuation of tumorigenicity by TFF1 in PC/AA/C1 and MDCKts.src cells The biological significance of the transforming functions of TFF1 observed in vitro was next examined using subcutaneous xenografts from parental and TFF1-transformed PC and MDCKts.src cell in the nude mice. About 10 7 PC-pcDNA3 and PC-TFF1 cells were injected subcutaneously in the right flank of each animal. Tumor growth was measured every 2 weeks, and tumor weight at day 110 after inoculation. As shown in Figure 2c , ectopic expression of TFF1 induced the tumorigenic potential in the premalignant PC cell line (Po0.05), since PC-pcDNA3 cells produced no or very small tumefaction at day 110. After injection of 10 7 cells, MDCKts.src-TFF1 xenografts showed the most striking difference in growth pattern. In this model, a positive cooperation between TFF1 and src was observed on tumor growth rate and time of tumor onset (Po0.001). We also detected a local invasion of the muscular wall in the flank of the mice bearing the MDCKts.src-TFF1 xenogratfs, whereas the MDCKts.src-pcDNA3 tumors were encapsulated (not shown). Thus, ectopic expression of TFF1 in colon adenoma and carcinoma cells is associated with the exacerbation of several detrimental transforming activities in the present study, including anchorageindependent growth in soft agar, invasiveness and tumorigenicity.
Identification of TFF1 target genes
Recent advances in TFF research indicate their implication in protein folding, intermolecular associations, TFF1 transforming functions and Cdc25 phosphatases S Rodrigues et al signal transduction and transcription of target genes (Tomasetto et al., 2000; Emami et al., 2001; Torres et al., 2002) . For example, we have recently demonstrated that TFF3 initiated STAT-3 signalling and cellular invasion through STAT-3-dependent signalling pathways in HCT8/S11 cells (Rivat et al., 2005) . In order to identify putative TFF1 target genes involved in cell transformation, we used the restriction fragment differential display-PCR methodology (RFDD-PCR) to investigate the transcripts differentially expressed in parental and TFF1-transformed HCT8/S11 cells. We isolated 224 cDNAs corresponding to differentially expressed transcripts. As some of them were redundant or originated from the same gene transcripts, we identified 90 individual genes linked to the ectopic expression of TFF1. We classified these genes into functionally distinct classes (Table 1 ). The majority of these genes are implicated in the regulation of cell proliferation, apoptosis, signaling and gene expression. The differential expression of a subset of 52 selected genes was analysed by semi-quantitative RT-PCR regarding their differential expression versus GAPDH in Transcripts levels induced by TFF1 are quoted in bold, other transcripts are downregulated.
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HCT8/S11-TFF1 cells, using the ImageQuant Software (not shown). As expected, TFF1 transcripts were strongly induced in HCT8/S11-TFF1 cells, versus their respective controls (vide infra).
Increased expression of Cdc25 phosphatases in TFF1-transformed cells and during human colorectal tumorigenesis As shown in Figure 3a , the differential expression of the Cdc25 homologues encoding the dual specific phosphatases called Cdc25A, B and C was confirmed by RT-PCR in TFF1-transformed HCT8/S11-TFF1 cells. Most interestingly, transformation of HCT8/S11-TFF1 and PC-TFF1 cells by the trefoil factor was associated with accumulation of the Cdc25A and B proteins by Western blot (Figure 3a) . In PC/AA/C1-TFF1 cells, transcripts levels of Cdc25a, b and c were not increased as compared to parental PC/AA/C1 cells (not shown), indicating that Cdc25s are also post-transcriptionnaly regulated by TFF1. For example, Cdc25A protein has a short half-life, is regulated in a cell cycle-dependent manner by nuclear import/ export, subcellular localization, 14-3-3 binding and cytoplasmic sequestration, and b-TrCP/proteasome-mediated degradation (Boutros et al., 2006) . In breast cancer patients, the abundance of Cdc25A is mainly the result of increased stability rather than increased transcript accumulation (Lo¨ffler et al., 2003) . The human phosphatase Cdc25A is an oncogenic protein (Galaktionov et al., 1995) . Both Cdc25a and b genes are involved in tumor growth and play critical roles in regulating apoptosis and cell cycle progression (Mitra and Enders, 2004; Brezak et al., 2005) . Increased expression of Cdc25A, B and C in active dephosphorylated forms are observed in aggressive human cancers (Kallstrom et al., 2005) . For example, Cdc25A was found overexpressed in breast cancers and this signal is associated with a poor survival (Cangi et al., 2000) . We have, therefore, analysed the phosphorylation status of Cdc25A and B in HCT8/S11-TFF1 cells. Each protein was immunoprecipitated using specific Cdc25A and B antibodies (IP), and then probed with anti-phosphotyrosine antibodies (WB). Conversely, phospho-proteins were immunoprecipitated and blotted with these anti-Cdc25A/B specific antibodies (not shown as similar results were obtained). Interestingly, increased levels of total Cdc25A and B proteins (Figure 3a , right panel) were not associated with a corresponding elevation of the Cdc25A and B phosphorylated forms (Figure 3a , lower panel). Our data support the notion that both proteins are induced under dephosphorylated forms by TFF1, leading to global increase of Cdc25A and B phosphatase activity.
To extend these results, we next investigated the status of Cdc25a and b during the neoplastic progression of human colon tumors (Figure 3b ). Both Cdc25a and b transcripts were found upregulated 1.8-to 8-fold by RT-PCR in human colon tumours (T), as compared to their corresponding adjacent histologically normal colon mucosa (M). In agreement with Figure 1 , TFF1 transcripts levels were increased according to a similar extent (1.8-to 8-fold) in all tumour samples, as compared to control adjacent specimen, suggesting a causal relationship between TFF1 up-regulation and increased expression of Cdc25A and B during colon cancer progression in vitro and in vivo. Another aspect of Cdc25s regulation is the generation of alternative splicing isoforms from the Cdc25a and b genes (respectively 236/116 and 521/479 bp), as shown here in human colorectal tumors (Figure 3b ). The 116bp transcript was not detected in the HCT8/S11 cell line, suggesting that tumor microenvironmental factors such as inflammatory and oxydative stress may be important for Cdc25 splicing signals and transcript stability. Splicing isoforms can also arise from noncancer cells in the tumor stroma, including endothelial, mesenchymal, and immune components. In human solid tumors of the colon and prostate, alternatively spliced Cdc25s variants correlated with agressive disease, recurrence and differentiation (Hernandez et al, 2001; Ozen and Ittmann, 2005) . Molecular identification and functional 
significance of these Cdc25 splice variants remains to be elucidated.
Increased cell survival in TFF1-transformed colon epithelial cells
Previous studies have demonstrated that both TFF1 and Cdc25A are involved in the regulation of cell proliferation and apoptosis (Bossenmeyer-Pourie et al., 2002; Kang et al., 2004; Leisser et al., 2004) . Consistent with this, we next examined the impact of TFF1 ectopic expression on cell survival in TFF1-transformed colon epithelial cells, using the potent apoptosis inducer thapsigargin (TG). As shown in Figure 4a , ectopic expression of TFF1 reduced by 10-20% the apoptosis induced by TG in PC and HCT8/S11 cells, respectively (Po0.05). To identify the mechanisms implicated in the protective role of TFF1 against apoptosis, we focused on critical survival effectors and signals of the death pathways, including the anti-apoptotic protein Bcl-2, the E3 ubiquitin ligase MDM2, and cleavage of the poly (ADP-ribose) polymerase-1 (PARP) as a common signature of the intrinsic apoptosis (Hipfner and Cohen, 2004) . Western blot analysis showed that TG treatment induced the expression of the cleaved active form of PARP in HCT8/S11 and PC cells, yielding a characteristic cleaved PARP 85 kDa fragment (Figure 4b ). Accordingly, intact PARP (116 kDa) was strongly downregulated by TG treatment in these two models.
As expected from our FACS analysis, the PARP cleavage was reduced or absent in TFF1-transformed cells. Moreover, forced expression of TFF1 counteracts by 76 and 58% the Bcl-2 protein loss observed after TG treatment in HCT8/S11 and PC cells, respectively. A similar picture was shown for the anti-apoptotic MDM2 protein, identified by the DDRT method (Table 1) , in TFF1-transformed and parental HCT8/S11 cells (73% recovery). A strong MDM2 signal was observed in HCT8/S11 cells, as compared to premalignant PC cells. PC-TFF1 cells harbor higher MDM2 levels, as compared to their PC counterparts. Interestingly, induction of apoptosis by TG resulted in marked downregulation of TFF1 levels in parental and TFF1-transformed HCT8/S11 colon cancer cells, as well as in human breast cancer cells MCF-7 expressing high levels of endogenous TFF1 (Figure 4c ). Our data suggest that TFF1 is a cell survival factor that is subjected to downregulation during induced apoptosis in cancer cells.
Discussion
Recent studies indicate that TFFs exert dual roles during normal development and malignancies associated with the digestive tract, especially inflammatory processes and cancer progression (Emami et al., 2004; Dhar et al., 2005) . During transient injury of the mucosa, TFFs display protective roles on mucosal repair and inflammation. Adverse actions of TFFs are linked to chronic inflammation and the neoplastic transformation. In human colon mucosa, the adenoma-carcinoma transition is the hallmark of the neoplastic progression and is associated with the invasive potential of cancer cells. Here, we show that TFF1 promotes the adenomacarcinoma transition in premalignant PC cells established from a patient with FAP. We added evidence that TFF1 overexpression potentiates the tumorigenicity of src-transformed MDCKts.src cancer cells in the nude mice. These findings suggest that TFF1 plays pejorative roles at early and late stages of colon cancer progression. To gain insight into the mechanisms linked to the transforming potential of TFF1, we showed that constitutive expression of TFF1 induced anchorageindependent cell growth in soft agar and cellular invasion through several proinvasive signaling pathways, including Rho-GTPases, Rho-kinase, PI3-kinase, PLC and COX-2. This picture is reminiscent to our TFF1 transforming functions and Cdc25 phosphatases S Rodrigues et al previous data on invasion and angiogenesis induced by external addition of the intact peptide TFF1 (Emami et al., 2001; Rodrigues et al., 2001 Rodrigues et al., , 2003b . Moreover, TFF1 overexpression induced resistance to apoptosis, as shown here by PARP cleavage and persistence of the two anti-apoptotic proteins Bcl-2 and MDM2. MDM2 is also found overexpressed or amplified in a wide variety of sarcoma, leukemia and other cancers, and controls many functions linked to cell proliferation and apoptosis, a situation associated with a poor prognosis (Moore et al., 2003; Onel and Cordon-Cardo, 2004; Zhang et al., 2004) . A positive correlation between MDM2 and Bcl-2 levels has been identified during malignant transformation (Soufla et al., 2005) . Our data confirm the notion that TFF1 is a survival factor (Bossenmeyer-Pourie et al., 2002) involved in cellular protection against several forms of apoptosis.
Forced expression of TFF1 induced Cdc25A and B protein levels in PC/AA/C1 adenoma cells and HCT8/ S11 colon cancer cells. This regulation is associated with increased expression of the active dephosphorylated forms of the phosphatases. Elevated expression of Cdc25A and B has been described in several malignancies (Boutros et al., 2006) , including human carcinomas of the breast and lung tumors. In colorectal cancer patients, overexpression of Cdc25B protein phosphatase is a marker of poor prognosis (Takemasa et al., 2000) . The nuclear phosphatases Cdc25A and B are potential oncogenic proteins associated with cell proliferation, foci formation, hypergrowth activity, and control of the G2/M checkpoint in response to DNA damage (Galaktionov et al., 1995; Daga and Jimenez, 1999; Xu et al., 2003; Boutros et al., 2006) . The biological rationale of our results is further sustained by the induction of TFF1 in inflammatory hyperplastic polyps, premalignant and early stages of colon cancer, as shown here by RT-PCR, immunohistochemistry, and previously by immunoblot analysis (Emami et al., 2001) . Importantly, we observed a concomitant induction of TFF1 and Cdc25a/b transcript levels during the progression of human colorectal tumors, suggesting a causal signal linkage between TFF1 levels and Cdc25 phosphatases expression and activity. Consistently, both TFF1 and Cdc25A are estrogen-regulated genes. To our knowledge, there is no information on the TFF1 halflife and degradation pathways in intact cells. TFF1 gene and protein expression are regulated by promoter methylation and loss of heterozygosity in human gastric cancers. We found that TFF1 protein levels are downregulated by apoptosis in parental and TFF1-transformed colon cancer cells, as well as in MCF-7 human breast cancer cells expressing high TFF1 levels. Moreover, TFF1 protein levels are also depleted by serum privation and hypoxia in this estrogen-dependent cancer cell line (not shown). It is therefore tempting to speculate that several potential mechanisms are involved in apoptosis-mediated TFF1 deregulation, including negative autoregulatory mechanisms using proteasomemediated degradation of this trefoil factor.
In conclusion, we have shown that TFF1 may be involved in the neoplastic progression of colon epithelial cells at two levels, namely the adenoma-carcinoma transitions and in established adenocarcinoma cells. The impact of transient or persistent signals associated with TFF1 induction and overexpression during chronic inflammatory conditions and the neoplastic progression should be examined in relation with their integration with other dominant oncogenic pathways implicated in these transitions in the intestine. These molecular alterations in adenoma PC/AA/C1 cells include the src and ras oncogenes, deficiencies in the APC tumor suppressor/b-catenin pathways, and induction of the active forms of the Cdc25 protein phosphatases by TFF1 in the present study. In agreement, Cdc25A and Cdc25B but not Cdc25C cooperate with activated Ras and loss of the pRb1 retinoblastoma tumor suppressor to transform primary rodent cells (Galaktionov et al, 1995) . Validation of this model can be explored in transgenic animals harboring selectively these oncogenic alterations, in cooperation with forced expression of TFF1 in intestinal stem cells, through intestinal promoters that are functional in this cellular compartment, such as the villin (pVIL) and carcinoembryonic antigen (pCEA) regulatory regions. Taken together, our data validate the therapeutic targeting of the TFF1 and Cdc25 signaling pathways (Brezak et al., 2005) in colon and breast cancer patients with TFF1-positive tumors.
Materials and methods
Immunohistochemistry
Surgical specimens from colorectomy performed for colorectal tumor carcinoma were retrieved from the files of the Department of Pathology, Saint-Antoine Hospital. To include cancers secondary to various types of molecular and genetic mechanisms, the following groups were studied: (i) cancers developed on familial adenomatous polyposis (FAP, n ¼ 3), (ii) hereditary nonpolyposis colorectal cancers (HNPCC, n ¼ 3), (iii) sporadic cancers with or without microsatellite instability (MSI, n ¼ 6). All specimens included one adenocarcinoma and at least one adenoma, and hyperplastic polys were present in some cases. Therefore, the following specimens were studied by immunohistochemistry, as described (Jourdan et al., 2003) : normal mucosa (n ¼ 12), hyperplastic polyps (n ¼ 3), adenomas (n ¼ 12) and adenocarcinomad (n ¼ 12). The slides were revealed by the mAb p2802 directed against TFF1 (1:40), a generous gift from Dr MC Rio. The bound antibody was detected with a Super Sensitive Detection kit (BioGenex, San Ramon, CA, USA). The slides were counterstained with hematoxylin.
Cell lines and culture conditions
Human adenomatous PC colon cells and MCF-7 breast cancer cells were cultured in DMEM supplemented with 10-20% foetal bovine serum (Empereur et al., 1997) . HCT8/S11 colon cancer cells were cultured in RPMI-1640 containing 10% FCS (Rodrigues et al., 2001) . MCF-7 were also cultured under growth factor-free, estrogen-free and hypoxic conditions using the OXOID incubator chamber (Basingtoke, Hamshire, England). The MDCKts.src cell line established after stable transfection of MDCK cells with a thermosensitive mutant of v-src (Behrens et al., 1993) was maintained in DMEM containing 10% FCS. . The invasion index is the percentage of cells invading the gel over the total number of cells (Bracke et al., 2001) . Data are means7s.e.m of three independent experiments. The differences between experimental values was assessed by the unpaired Student's t-test and Po0.05 or better (*) was considered to be statistically significant. The impact of TFF1 and TG on cell apoptosis was determined by flow cytometry (FACS Caliburn cytofluorometer, Becton Dickinson) after staining of the cells with propidium iodide (50 mg/ml).
Tumor growth in nude mice PC-pcDNA3, PC-TFF1, MDCKts.src-pcDNA3 and MDCKts.src-TFF1 cells were harvested by trypsin/EDTA at the exponential phase of growth, and resuspended in phosphate-buffer saline (PBS). For each group, about 10 7 cells in 100 ml of PBS were xenografted subcutaneously in the flank of eight female 5-week-old athymic nude mice. Tumor formation was assessed twice a month.
Differential display and PCR analysis
Total RNA from HCT8/S11-pcDNA3 and HCT8/S11-TFF1 cell lines was extracted using Trizol (Invitrogen). Poly(A) þ RNA was prepared with Oligotext mRNA isolation kit (Quiagen Courtaboeuf, France) according to the manufacturer's protocols. Reverse transcription was performed using Superscriptt and hexarandom primers (Invitrogen). The mRNA expression profile analysis was performed using the display PROFILE TM kit (QBiogene, Illkirsh, France). Excised cDNA amplicons exhibiting differential expression profiles were reamplified by PCR, purified using QIAquick gel extraction (Quiagen), ligated into pCR4 Topo TA cloning vector (Invitrogen), and sequenced using an automated fluorescence-based sequencer (MilleGene, Toulouse, France). Sequences were compared by Blast to current GenEMBL and dBEST databases. For each of the isolated cDNA fragment a pair of specific primers was synthesized and differential gene expression was validated and confirmed by semi-quantitative RT-PCR analysis. Cdc25a, b, c and GADPH amplifications were performed using the following set of primers: Cdc25a, forward 5 0 -GAAGAGGCCATTCTGATTC-3 0 , reverse 5 0 -TGAAATTCCCTGGTTCACTGC-3 0 ; Cdc25b, forward 5 0 -CCAGGCTCGGCTCTCAGTC-3 0 , reverse 5 0 -CCACTGCC CGCCTCGCTC-3 0 ; Cdc25c, forward 5 0 -TGGTGATTCTG-CAAACCTAAGC-3 0 , reverse 5 0 -ATCTGAAATCTCTTCT GCCTGG-3 0 ; TFF1, forward 5 0 -GAGAACAAGGTGATC TGCGC-3 0 , reverse 5 0 -TGGTATTAGGATAGAAGCACC-3 0 ; GAPDH forward 5 0 -ATCACCATCTTCCAGGA GCG-3 0 , reverse 5 0 -CCTGCTTCACCACCTTCTTG-3 0 . PCR reactions were performed as described previously (Rodrigue et al., 2005) .
Reagents
The prostaglandin H2/ thromboxane A2 receptor (TXA2-R) antagonist SQ29,548 (designated as SQ295 in the present study) was from Cayman Chemicals (Ann Arbor, MI, USA), and thapsigargin from Sigma (Lyon, France). Wortmannin (WORT), U73122 and NS398 were from Calbiochem (Meudon, France). Clostridium botulinum exoenzyme C3 transferase (C3T) was a generous gift from Dr Flatau (INSERM U627 Nice, France). Y27632 was from Yoshitomi Pharmaceutical Industries (Osaka, Japan).
